Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Batiste-Alentorn E, Sáenz A, López-Brea M, Font A, Nogué M, Bastús R, Climent MA, de la Cruz JJ, Albanell J, Banús JM, Gallardo E, Diaz-Rubio E, Cortés-Funes H, Baselga J. Bellmunt J, et al. Among authors: nogue m. J Clin Oncol. 2000 Sep 15;18(18):3247-55. doi: 10.1200/JCO.2000.18.18.3247. J Clin Oncol. 2000. PMID: 10986057 Clinical Trial.
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.
Carles J, Font A, Mellado B, Domenech M, Gallardo E, González-Larriba JL, Catalan G, Alfaro J, Gonzalez Del Alba A, Nogué M, Lianes P, Tello JM. Carles J, et al. Among authors: nogue m. Br J Cancer. 2007 Nov 5;97(9):1206-10. doi: 10.1038/sj.bjc.6604030. Epub 2007 Oct 23. Br J Cancer. 2007. PMID: 17955053 Free PMC article. Clinical Trial.
Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.
Carles J, Nogue M, Sole JM, Foro P, Domenech M, Suarez M, Gallardo E, García D, Ferrer F, Gelabert-Mas A, Gayo J, Fabregat X. Carles J, et al. Among authors: nogue m. Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1085-91. doi: 10.1016/j.ijrobp.2009.03.024. Epub 2009 Jul 4. Int J Radiat Oncol Biol Phys. 2010. PMID: 19577864 Clinical Trial.
Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial.
Vidal J, Casadevall D, Bellosillo B, Pericay C, Garcia-Carbonero R, Losa F, Layos L, Alonso V, Capdevila J, Gallego J, Vera R, Salud A, Martin-Richard M, Nogué M, Cillán E, Maurel J, Faull I, Raymond V, Fernández-Martos C, Montagut C. Vidal J, et al. Among authors: nogue m. Clin Cancer Res. 2021 May 15;27(10):2890-2898. doi: 10.1158/1078-0432.CCR-20-4769. Epub 2021 Mar 16. Clin Cancer Res. 2021. PMID: 33727257 Clinical Trial.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
35 results